Analystreport

Biohaven Pharmaceutical (NYSE: BHVN) was given a new $34.00 price target on by analysts at Canaccord Genuity. They now have a "buy" rating on the stock.

Biohaven Ltd. Common Shares  (BHVN) 
Last biohaven ltd. common shares earnings: 2/25 04:45 pm Check Earnings Report
US:NYSE Investor Relations: investors.biohavenpharma.com